

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUSCOKE RESOURCES HOLDINGS LIMITED**

### **和嘉資源控股有限公司**

**(To be renamed as “Huscoke Holdings Limited”)**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 704)**

#### **(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION COMMITTEE; AND**

#### **(2) COMPLIANCE WITH RULE 3.10(1) OF THE LISTING RULES**

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Huscoke Resources Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Wang Wei Hsin (“**Dr. Wang**”) has been appointed as (i) the independent non-executive Director; (ii) the member of the audit committee of the Company; (iii) the member of the remuneration committee of the Company; and (iv) the member of the nomination committee of the Company with effect from 19 December 2018. The biographical details of Dr. Wang are set out as follows:

#### **Biography of Dr. Wang**

Dr. Wang Wei Hsin, aged 52, has been appointed as an independent non-executive Director of the Company with effect from 19 December 2018. Dr. Wang has extensive management experience in the financial services industry. Dr. Wang served as the chief executive officer of South China Financial Holdings Limited (“**South China Financial**”), a company the issued shares of which are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (Stock Code: 619), and certain subsidiaries of South China Financial from May 2016 to October 2018, and served as executive director of South China Financial from March 2017 to October 2018. Dr. Wang served as the chairman and chief executive officer of SinoPac Securities (Asia) Limited and was responsible for the business development and operations in Asia from 2009 to 2016. He also served as the chief investment officer of Japan CDW Group and the chief financial officer of its Taiwan subsidiary, as well as co-founder of Yes-Asia.com and played significant role in China Development Industrial Bank.

Dr. Wang held a PhD in Management Science (Financial Engineering) from Imperial College London and researched artificial intelligence and financial big data. Dr. Wang was the fellow of Royal Society of Statistics during 1999 to 2000.

Dr. Wang has not entered into any service agreement with the Company regarding his appointment. He shall hold office until the next annual general meeting of the Company and retire at that general meeting but be eligible for re-election pursuant to the bye-laws of the Company. Dr. Wang is entitled to a monthly director fee of HK\$10,000, which was determined by the remuneration committee of the Company with reference to his duties and responsibilities within the Group, the Group's remuneration policy and the prevailing market condition. He is also entitled to a discretionary bonus for each financial year, which is payable at the discretion of the Board (or, if so delegated, the remuneration committee of the Board) and determined with reference to the Group's results and performance for the financial year concerned.

Save as disclosed above, as at the date of this announcement, Dr. Wang (i) does not hold any position with the Company or other members of the Group; (ii) does not have any relationship with any Director, senior management, substantial or controlling shareholder of the Company (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")); (iii) has not held any directorship in public companies in the last three years the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not have any interests in the securities of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. Wang confirmed that he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there is no other information which is required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules and there are no matters relating to the appointment of Dr. Wang which the Board considers necessary to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity express its warmest welcome to Dr. Wang in joining the Company.

#### **COMPLIANCE WITH RULE 3.10(1) of LISTING RULES**

Following the appointment of Dr. Wang as the independent non-executive Director, the Board comprises two executive Directors, two non-executive Directors and three independent non-executive Directors. The Company is in compliance with the requirement of having a minimum of three independent non-executive Directors on the Board of Directors under Rule 3.10(1) of the Listing Rules.

By order of the Board of  
**Huscoke Resources Holdings Limited**  
**So Chiu Fung**  
*Executive Director*

Hong Kong, 19 December 2018

*As at the date of this announcement, the Board comprises Mr. Zhao Xu Guang and Mr. So Chiu Fung as executive Directors; Mr. Wong Siu Hung, Patrick and Mr. Huang Man Yem as non-executive Directors; Mr. Lam Hoy Lee, Laurie, Mr. To Wing Tim, Paddy and Dr. Wang Wei Hsin as independent non-executive Directors.*